ArticleScientific reports2025
Multimodal prediction of metastatic relapse using federated deep learning in soft-tissue sarcoma with a complex genomic profile.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Automated detection of primary soft tissue sarcomas of the extremities using artificial intelligence and ChatGPT.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft Tissue sarcomas (STS) are a group of heterogeneous and complex diseases where being able to predict the appearance of metastases is key to inform clinical decisions, especially the prescription of adjuvant chemotherapy. We developed SarcNet: a multimodal deep-learning algorithm based on histological whole-slides and clinical variables to predict metastatic relapse in patients affected with limbs and trunk wall STS. Two independent series were investigated simultaneously in a privacy-enhanced multicentric setup using Federated Learning: Centre Léon Bérard (n = 221) and Institut Bergonié (n = 390). We then collected two additional validation cohorts from Centre Léon Bérard (n = 93) and Institut Bergonié (n = 124) to validate the performance of the trained algorithm. Evaluated in cross-validation setting on the first two cohorts, SarcNet achieved a performance of 0.797 AUC (Area Under the Receiver-operating characteristic Curve, 0.762-0.833) to predict 5-year MFS comparable to the Sarculator, current state-of-the-art nomogram (0.778 (0.743-0.814)), and outperforming the FNCLCC grading, widely used in practice (0.706 (0.670-0.743), P-value < 0.001). On validation cohorts, SarcNet performance is still on-par to the Sarculator and FNCLCC rating. Interpretability investigations of SarcNet highlighted histological patterns driving the prediction of metastatic relapse such as atypia, tumor cellularity and anisokaryosis. This model may assist clinical decisions by identifying high-risk patients that could benefit from neoadjuvant or adjuvant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.